Y Intercept Hong Kong Ltd Takes $9.13 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Y Intercept Hong Kong Ltd acquired a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 302,995 shares of the company’s stock, valued at approximately $9,126,000.

Other institutional investors have also modified their holdings of the company. Aster Capital Management DIFC Ltd bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at about $25,000. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust lifted its holdings in Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TEVA. Truist Financial lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Piper Sandler restated an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Trading Down 0.2%

Shares of TEVA opened at $34.55 on Friday. The business’s 50-day moving average price is $33.96 and its 200 day moving average price is $32.55. The stock has a market capitalization of $39.73 billion, a P/E ratio of 25.98, a P/E/G ratio of 4.23 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the sale, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. This represents a 61.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at $1,973,727. This represents a 34.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 465,931 shares of company stock valued at $16,332,989 over the last three months. 0.54% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.